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Abstract
Problem Bronchiolitis is the leading diagnosis of hospitalizations for children under oneyear. The purpose of this study was to evaluate the effectiveness of supportive high-flow
oxygen (HFO) therapy for infant patients requiring more than 2L/min nasal cannula
(NC).
Methods An observational, descriptive design with convenience sampling of infants aged
one-year or less, hospitalized with bronchiolitis and requiring HFO therapy. Comparisons
were done between 2019 when no HFO was allowed on the general unit and in 2020
when HFO was allowed.
Results Of 28 patients (N = 28), 13 (n = 13) were in the 2019 cohort and 15 (n = 15) in
2020. A Fischer’s exact test indicated a general unit admission in 2020 was not likely to
result in a pediatric intensive care unit (PICU) transfer. Significant positive associations
were evident between length of oxygen therapy and length of stay (LOS) in 2019 (rp =
0.95, p<.001) and 2020 (rp = 1.00, p<.001); length of oxygen therapy and length of HFO
therapy (rp = 0.77, p = .015); and LOS and length of HFO therapy (rp = 0.80, p = .010) in
2020. No differences emerged between rates of initial PICU admissions, PICU transfers,
length of oxygen therapy, length of HFO therapy, PICU LOS, or LOS between cohorts.
Implications for Practice Use of HFO therapy on the general unit was associated with
decreases in frequency of PICU transfers and initial admissions, but no changes occurred
in length of oxygen therapy, length of HFO therapy, PICU LOS, or total LOS.
Keywords: 2019 cohort, 2020 cohort, bronchiolitis, high-flow oxygen, length of stay,
low-flow oxygen, nasal cannula, pediatric intensive care unit, pediatric unit, transfers
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Utilizing High Flow Oxygen Therapy In Infants With Bronchiolitis
The American Academy of Pediatrics (AAP) defines bronchiolitis as a viral
illness involving the lower airways resulting in acute inflammation and swelling, an
overproduction of mucous, and destruction of epithelial cells coating the inner lining of
airways (Ralston et al., 2014). The etiology of bronchiolitis is attributed to many
respiratory viruses, with the most frequent infections occurring between the months of
November through April (Ralston et al., 2014).
Bronchiolitis is the leading diagnosis for pediatric inpatient hospitalizations for
children under a year of age, contributing to a persistent burden of disease and risk of
rapid physiologic deterioration (Ralston et al., 2014). Consequently, one in every eight
pediatric patients hospitalized for bronchiolitis requires admission to the PICU for HFO
delivery, continuous positive airway pressure (CPAP) or other means of supportive
respiratory therapy (Schlapbach et al., 2017). Furthermore, costs associated with inpatient
bronchiolitis-related care have exceeded $1.73 billion per year with greater than 100,000
pediatric hospitalizations per year (Schlapbach et al., 2017; Ralston et al., 2014).
Children under one year of age constituted the highest percentage of overall costs
(52.9%) and volume (67.9%) of hospital stays in 2016 (Moore, Freeman, & Jiang, 2019;
Douchette et al., 2016).
Current clinical practice guidelines have recommended supportive treatment only
for bronchiolitis care (Ralston et al., 2014). Modes of inpatient bronchiolitis supportive
treatment ranges from low flow oxygen (LFO) therapy, HFO therapy, CPAP, or the more
invasive treatments of intubation and mechanical ventilation. While LFO therapy may be
effective for milder cases, more severe cases of bronchiolitis may be effectively treated
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with the use of HFO therapy or heated and humidified high flow (HHHF) therapy, a
subset of HFO therapy.
At a suburban, Midwestern pediatric hospital, prior practice was infants one year
or younger on the general pediatric unit requiring more than the maximum respiratory
support, defined as more than 2L/min with NC, to be admitted to the PICU. This creates
potential for over-utilization of PICU resources and increased costs for patients who may
be capable of receiving safe, effective care on a general pediatric unit. As part of a quality
improvement (QI) initiative, in September 2019, a new process change included the
admission of infants to the general pediatric unit for supportive oxygen therapy up to
6L/min NC or up to 50% fraction of inspired oxygen (FiO2) with a venturi mask. At the
clinical site of interest, the prior maximum respiratory support on the general pediatric
unit in 2019 was defined as oxygen delivery of up to 2L/min NC or up to 50% oxygen via
mask. The purpose of this QI initiative was to evaluate the effectiveness of an increased
allowance of supportive oxygen therapy for infant patients requiring up to 6L/min NC on
a general pediatric unit. The aim of this project was to reduce PICU admissions for
supportive HFO therapy of infants with bronchiolitis by 15%. The outcome measures of
interest were the number of initial general unit admissions, the number of initial PICU
admissions, number of PICU transfers, total length of supportive oxygen therapy, total
length of HFO therapy, PICU LOS, and the total hospital LOS. The question for study
was: in hospitalized infants under one-year of age diagnosed with bronchiolitis, what is
the effect of general unit-based HFO therapy compared to PICU-based HFO therapy on
PICU transfers, PICU admissions, length of supportive oxygen therapy, length of HFO
therapy, PICU LOS, and total hospital LOS, during the peak of bronchiolitis season?
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Review of Literature
The databases searched for this review were the Cochrane Database of Systematic
Reviews, CINAHL, Google Scholar, Medline, and national health care databases, such as
the Agency for Healthcare Research and Quality (AHRQ), Centers for Disease Control
and Prevention (CDC), and the Healthcare Cost and Utilization Project (HCUP). Key
search terms were picu, pediatric, low flow, high flow, high flow therapy, pediatric floor,
general floor, bronchiolitis, and infant, using the Boolean operators AND and OR. The
literature review included all publications from 2014 to 2019, full-text and written in
English. Publications were excluded if the principal objectives were to examine
outpatient or home therapy treatments, premature infants, and children with a history of
any chronic medical condition. In addition, an ancestry method was used from relevant
publications. The search yielded nine publications, including one systematic review, two
randomized control trials (RCT), one case-control study, and four retrospective studies of
which three contained a pre- and post-intervention component. The following themes
emerged from the evidence regarding bronchiolitis management: effectiveness of high
flow oxygen therapy, and setting-dependent differences in LOS and costs.
The effectiveness of HFO therapy for bronchiolitis management was featured
prominently in several publications. A study by Mayfield, Bogossian, O’Malley, and
Schibler (2014) discovered significant decreases in heart rate (HR) and respiratory rate
(RR) for infants treated with HFO therapy. The authors’ definition of HFO therapy was a
flow rate greater than 2L/kg/min per NC (max 10L/min). Their case-control study found
patients on HFO on the general pediatric unit were four times less likely to require
transfer to the PICU as compared to patients on LFO therapy (Mayfield et al., 2014).
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Infants who responded to HFO displayed a statistically significant decrease (p<0.002) in
HR and RR in comparison to patients on LFO therapy (Mayfield et al., 2014).
Limitations of this study included being a case-control study, non-randomization of
patients, and small sample size (N=94) (Mayfield et al., 2014). Mayfield et al. (2014)
concluded patients on HFO therapy could be safely managed on a general pediatric floor;
however, the authors emphasized the need for future RCTs to strengthen evidence for the
safe use of HFO therapy on a general pediatric unit.
Kepreotes et al., (2017) commenced a RCT of children under 2 years of age
diagnosed with bronchiolitis. Patients were randomly assigned to either a standard, low
flow cold oxygen therapy (LFCO) (max 2L/min NC) or a high flow warmed humidified
oxygen (HFWHO) therapy, defined as 1L/kg/min NC to a max of 20L/min NC
(Kepreotes et al., 2017). They found twice as many patients in the LFCO therapy group
suffered treatment failure, defined as requirement of higher level of care, when compared
to patients on HFWHO (33 [LFCO] vs 14 [HFWHO], p=0.0016). More HFWHO patients
remained failure-free after 24-hours (90% [HFWHO] vs 60% [LFCO], p<0.0001) versus
LFCO patients (Kepreotes et al., 2017). Additionally, two-thirds of the LFCO therapy
patients demonstrated improvement when placed on HFWHO and avoided a PICU
admission (Kepreotes et al., 2017). This RCT offered compelling support for the
effectiveness in HFO therapy improving a patient’s clinical outcome.
Likewise, Franklin et al. (2018) conducted a RCT of infants receiving either LFO
(up to 2L/min NC) or HFO therapy (2L/kg/min NC) and studied how many patients in
both groups experienced treatment failure. Their results demonstrated a statistically
significant difference in patients who required treatment escalation between groups (167
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[LFO] vs 87 [HFO], p<0.001) (Franklin et al., 2018). Of 167 patients initially receiving
LFO, 102 of the 167 patients responded well to HFO therapy when therapy was escalated
(Franklin et al., 2018). The strengths of Franklin et al. (2018) study included their RCT
design, multi-center inclusion, and a large sample size (N=1,472). However, the Franklin
et al. (2018) study was limited in that HFO therapy only occurred within the PICU
setting; therefore, a comparison of HFO supportive care between the general floor and
PICU could not be determined.
Beggs, Wong, Kaul, Odgen, and Walters (2014) performed a systematic review to
assess for the effectiveness of HFO therapy compared to other types of respiratory
interventions (i.e., CPAP, oxygen tent, LFO, and non-invasive ventilation) in patients
with a bronchiolitis diagnosis. Only one published RCT met inclusive criteria (Hilliard et
al., 2012 cited in Beggs, et al., 2014). Hilliard et al., (2012) study considered HFO
therapy as oxygen rates greater than 4L/min NC. No statistical difference was observed in
LOS between LFO and HFO therapy (164 hours [LFO] vs 162 hours [HFO], p=0.7), or
total length of oxygen use (117 hours [LFO] vs 80 hours [HFO], p=0.32). Although well
designed, this RCT had only a small sample size (N=19) and was deficient in documented
clinical outcomes, thus limiting the strength of the evidence for the effectiveness of HFO
use for bronchiolitis management (Beggs et al., 2014).
Infants with bronchiolitis treated with HFO may experience a decreased LOS in
the hospital. Riese, Fierce, Riese, and Alverson (2015) demonstrated a substantial
decrease in LOS for patients on high-flow nasal cannula (HFNC) therapy attributed to a
policy change. A retrospective, non-randomized, pre- and post-intervention study
followed infants under 2 years of age utilizing HFNC treatment before and after the
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policy change. The old policy did not allow for the initiation or continuation of HFO on
the general pediatric unit, but the new change allowed patients on the general pediatric
unit to be started or continued on HFO (Riese et al., 2015). Maximum flow rate for
infants less than six months of age was up to 8L/min NC, infants six to 18 months of age
up to 12L/min NC, and toddlers 18 to 24 months of age up to 15L/min NC. Outcome
measures included LOS, total hospital costs and readmission rates, which were then
compared between the populations of interest (Riese et al., 2015). In HFO patients treated
on the general unit, a statistically significant decrease in LOS of one day (p<0.001) and
its associated hospital charges ($2,920, p<0.001) was discovered (Riese et al., 2015). This
investigation was the first to examine the relationship between HFNC use in bronchiolitis
patients and LOS. Limitations of the study included a single-site locale and difficulty
controlling for variables, such as seasonal variation or level of illness severity.
Regardless, the authors concluded bronchiolitis patients on HFNC therapy demonstrated
lower rates of LOS and costs; but emphasized additional investigations on patient
outcomes to strengthen the argument for the safe utilization of HFO therapy on the
general floor (Riese et al., 2015).
A repeat quasi-experimental study by Riese et al. (2017) was performed as a
follow-up to their first study for validation. LOS, PICU transfers, and readmission rates
in patients on HFNC therapy were studied (Riese et al., 2017). The same age-dependent
oxygen flow rates initiated previously were continued from the initial study. The 2017
inquiry included a larger cohort of patients evaluated (N=576) than the 2015 study
(N=290). In HFO patients treated on the general unit, a statistically significant decrease in
unadjusted days on HFNC (p<0.001) and mean LOS (p=0.02) was discovered, consistent
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with their first study findings (Riese et al., 2017). Hence, HFO for infants with
bronchiolitis was clinically beneficial and cost-effective.
Multiple studies have examined the costs associated with HFO therapy (Collins,
Chan, Roberts, Wren, & Wright, 2017; Heikkila, Forma, & Korppi, 2014; Riese et al.,
2015). Collins et al. (2017) quasi-experimental study assessed costs of PICU HFO and
general pediatric unit HFO via a simulated care model. Infants 30-90 days old could
receive up to 4L/min NC and patients 91 days to 2 years old could receive up to 6L/min
NC. Patients who received HFO therapy in the PICU accrued a 10% higher cost of care
when compared to patients who received care on the general pediatric unit (Collins et al.,
2017). While these costs were direct patient costs, incidental expenses, i.e. staff and
equipment costs were not itemized (Collins et al., 2017). Similarly, Heikkila et al. (2014)
performed a retrospective study to identify aspects of bronchiolitis care associated with
high hospital costs but differentiated these costs contingent upon setting. The results
established a strong positive correlation (r=0.960, p<0.001) of overall costs to total LOS
and length of PICU stay (Heikkila et al., 2014). Moreover, the cost per patient per day in
the PICU for bronchiolitis care was nearly four times higher than patients receiving
bronchiolitis care on the general pediatric floor (Heikkila et al., 2014). However, Heikkila
et al. (2014) study did not differentiate type of treatment modality used or if treatment
modality was consistent between the PICU and the general unit. Finally, Schlapbach et al.
(2017) aimed to measure admission rates, direct costs and patient outcomes before and
after the widespread use of HFO in a multicenter site study spanning ICUs in two
countries. The authors defined HFO therapy as a flow rate greater than 1L/min NC. They
discovered bronchiolitis was the primary diagnosis for admission to the ICU during the
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13-year time period, and the rates of ICU admission rose with the use of HFO
(Schlapbach et al., 2017). After widespread HFO initiation, HFO usage increased to 72%
with a subsequent decrease in the utilization of non-invasive ventilation (NIV), intubation
and mechanical ventilation (Schlapbach et al., 2017). While the average hospital LOS
decreased post-HFO usage (12.47 to 9.13 days, p<0.001), total direct costs more than
tripled (Schlapbach et al., 2017). The study’s implications demonstrated treatment for
bronchiolitis accounted for high hospital costs in the ICU setting; however, the use of
HFO demonstrated a cost savings when delivered on a general pediatric unit and an
overall decrease in LOS.
HFO therapy for bronchiolitis has been reported to provide safe and effective care
(Mayfield et al., 2014; Franklin et al., 2018; Riese et al., 2015; Riese et al., 2017;
Kepreotes et al., 2017) regardless of location. While some analyses found decreases in
LOS (Schlapbach et al., 2017; Riese et al., 2015; Riese et al., 2017), others did not
establish a link between HFO therapy and decreased LOS (Beggs et al., 2014; Mayfield
et al., 2014). With such variation, current practice guidelines need further research
focused on patient-centered outcomes in bronchiolitis treatment (Ralston et al., 2014).
The implementation of HFO therapy reduced the frequency of care escalations,
decreased associated healthcare costs and hospital LOS. Bronchiolitis care on a general
pediatric unit may produce a cost savings without compromising safety in the care
delivered (Collins et al., 2017; Heikkila et al., 2014). In summary, despite most of the
studies in this review demonstrating relatively safe, efficacious, and cost-effective care of
pediatric patients who received HFO therapy on the general unit, there are few published
studies of a strong design and subsequently, no major changes in current clinical practice
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have occurred. Further studies regarding HFO therapy for bronchiolitis delivered on a
general pediatric unit when compared to PICU-based care are needed.
A large, Midwestern, suburban medical center with a pediatric hospital previously
admitted infants under one year of age with bronchiolitis requiring more than 2L/min NC
of supportive oxygen therapy to the PICU. Based upon equipment availability, a process
change was implemented to admit infants on HFO to the general unit instead of the
PICU. This pilot test-of-change employed Deming’s Plan-Do-Study-Act (PDSA) cycle
for initiating and measuring the change (The W. Edwards Deming Institute, 2019).
Method
Design
The study was an observational, descriptive design. The method of evaluation was
a retrospective medical record review before (2019) and after (2020) a process change
during the bronchiolitis season. The 2019 process required bronchiolitis patients needing
a higher amount than standard supportive oxygen therapy (greater than 2L/min NC) to be
admitted and monitored in the PICU. The 2020 process change included admission of
patients in need of a higher amount of supportive oxygen therapy, up to 6L/min NC to the
general pediatric unit. This QI initiative evaluated patients over a three month period,
from February 1st, 2019 and 2020 through April 30th, 2019 and 2020, during the peak of
the bronchiolitis season.
Setting
The setting was a suburban, Midwestern children’s hospital PICU and general
pediatric unit located within a large medical center. The children’s hospital employs a
team of pediatric specialists in over 30 subspecialties, comprising the only 12-bed PICU
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in the suburban area, along with a 48-bed general pediatric inpatient unit and a separate
pediatric emergency department (ED).
Sample
This was a convenience sample of infants under one-year of age with a diagnosis
of bronchiolitis admitted to either the general pediatric unit or the PICU. Inclusion
criteria were: 1) a primary or secondary diagnosis of bronchiolitis or wheezing-associated
respiratory infection (WARI); and, 2) requirement of HFO therapy more than 2L/min
NC. Exclusion criteria were: 1) prematurity (before 37 weeks’ gestation); 2) a chronic
health condition that affected the pulmonary system; 3) requirement of equal to or less
than 2L/min NC supportive oxygen therapy; or 4) requirement of CPAP, non-invasive
ventilation, or intubation.
Approval Process
Approval was obtained from the pediatric administration at the medical center.
Additional approvals from the doctor of nursing practice (DNP) committee, the medical
center’s institutional review board (IRB) and the university’s IRB were acquired. Risks
of this study were potential breaches of patient confidentiality; however, this was a
retrospective medical record review removing all patient identifiers to minimize this risk.
Benefits of the project included knowledge gained in resource utilization and in patient
care of infants with bronchiolitis.
Data Collection/Analysis
Collected data included the demographics of gender, race, and age. In addition,
the number of initial general floor admissions, the number of initial PICU admissions, the
number of PICU transfers, total length of supportive oxygen therapy, length of HFO
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therapy, PICU LOS, and the total hospital LOS was recorded. All data was de-identified
and coded as 2019 cohort data and 2020 cohort data. Descriptive statistics were used, and
the inferential statistics of Fischer’s exact test, Pearson r correlation, and t-Tests were
completed. Intellectus Statistics (http://analyze.intellectusstatistics.com/) was used.
Results were considered significant at the .05 level.
Process
A team of stakeholders consisting of pediatric hospitalists, intensivists and
respiratory therapists was convened to address resource utilization for hospitalized infants
with bronchiolitis. After examining available respiratory equipment, a decision was made
to pilot the implementation of the use of HFO therapy via standard NC on the general
pediatric unit with the aim of improving patient outcomes and total hospital LOS.
Results
A total of 80 potential subjects were identified with a bronchiolitis diagnosis
during the 2019 period. Of those, 13 (N = 13) met inclusion criteria for study. The
predominant gender in the 2019 cohort was male (n = 10, 77%) with three patients being
female (n = 3, 23%). The predominant race was Caucasian (n = 12, 92.3%) with one
African-American patient (n = 1, 7.7%). The mean age of patients in the 2019 cohort was
9.8 weeks (SD = 5.6). One patient was 2-weeks old (7.7%); one patient was 4-weeks old
(7.7%); two patients were 5-weeks old (15.4%); one patient was 7-weeks old (7.7%);
three patients were 8-weeks old (23%); one patient was 12-weeks old (7.7%); three
patients were 16-weeks old (23%); and one patient was 20-weeks old (7.7%).
A total of 46 potential subjects were identified with a bronchiolitis diagnosis
during the 2020 time frame. Of those, 15 (N = 15) met inclusion criteria for study. The
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predominant gender in the 2020 cohort was female (n = 10, 66.7%), with five patients
being male (33.3%). The predominant race was Caucasian (n = 10, 66.7%) with three
African-American patients (20%) and two Asian-Indian patients (13.3%). The mean age
of patients in the 2020 cohort was 24.9 weeks (SD = 18.2). One patient was 3-weeks old
(6.6%); one patient was 4-weeks old (6.6%); one patient was 5-weeks old (6.6.%); one
patient was 6-weeks old (6.6%); one patient was 7-weeks old (6.6%); one patient was 8weeks old (6.6%); one patient was 16-weeks old (6.6%); one patient was 28-weeks old
(6.6%); one patient was 32-weeks old (6.6%); one patient was 40-weeks old (6.6%); four
patients were 44-weeks old (26.6%); and one patient was 48-weeks old (6.6%).
In the 2019 cohort, six patients (46%) were initially admitted to the general unit,
and seven (54%) were initially admitted to the PICU. Ultimately, all six patients (100%)
initially admitted to the general unit were transferred to the PICU for escalation of HFO
therapy. In the 2020 cohort, 11 patients (73%) were initially admitted to the general floor,
and four (27%) were initially admitted to the PICU. Five patients (45.5%) initially
admitted to the general floor were transferred to the PICU for escalation of HFO therapy
(Appendix A).
The patients in the 2019 cohort experienced a mean of 102.54 hours (SD = 66.93)
on supportive oxygen therapy, and a mean of 42.35 hours (SD = 23.82) for those on HFO
therapy in the PICU. Mean PICU LOS was 54.85 hours (SD = 32.49), and mean total
hospitalized LOS was 134.81 hours (SD = 103.45). The patients in the 2020 cohort
experienced a mean of 105.13 hours (SD = 90.24) on supportive oxygen therapy, with a
mean of 56.87 hours (SD = 64.12) for those on HFO therapy either on the general unit or
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in the PICU. The mean PICU LOS was 89.56 hours (SD = 75.52), and mean total
hospitalized LOS was 119.43 (SD = 93.84).
A Fischer’s Exact Test was used to examine if general unit admissions and PICU
transfers were independent of each other in the 2020 cohort. The initial general unit
admission rate in the 2020 cohort was 11 but five were transferred to the PICU (p =
.231). Hence, in 2020, a general unit admission was not likely to result in a transfer to
the PICU (Appendix B). A nonparametric test was unable to be performed on the 2019
cohort data due to the perfect collinearity of the data.
A Pearson r correlation was conducted to examine the relationship between
supportive oxygen therapy and total hospitalized LOS. A very strong relationship
between length of supportive oxygen therapy and total hospitalized LOS in the 2019
cohort (rp = 0.95, p<.001) was found. No other relationships were evident. In addition, a
perfect, direct relationship between length of oxygen therapy and total hospitalized LOS
was established in the 2020 cohort (rp = 1.00, p< .001). Also in the 2020 cohort, a very
strong relationship was established between length of supportive oxygen therapy and
length of HFO therapy (rp = 0.77, p = .015), and a very strong relationship was
established between total hospitalized LOS and length of HFO therapy (rp = 0.80, p =
.010). No other relationships were evident (Appendix C).
The independent samples paired t-test was performed to evaluate differences in
length of supportive oxygen therapy, HFO therapy, PICU LOS, and total hospitalized
LOS between the 2019 and 2020 cohorts. The mean length of supportive oxygen therapy
increased slightly from 102.54 hours (SD = 66.93) in the 2019 cohort to 105.13 hours
(SD = 90.24) in the 2020 cohort. The difference between means was not statistically
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significant at the .05 level (t = 0.09, d = 0.03, p = .933). The mean length of HFO therapy
increased from 42.35 hours (SD = 23.82) in the 2019 cohort to 56.87 hours (SD = 64.12)
in the 2020 cohort. The difference between means was not statistically significant at the
.05 level (t = 0.77, d = 0.30, p = .448). The mean PICU LOS increased from 54.85 hours
(SD = 32.49) in the 2019 cohort to 89.56 hours (SD = 75.52) in the 2020 cohort. The
difference between means was not statistically significant at the .05 level (t = 1.48, d =
0.60, p = .154). The mean total LOS decreased from 134.81 hours (SD = 103.45) in the
2019 cohort to 119.43 hours (SD = 93.84) in the 2020 cohort. The difference between
means was not statistically significant at the .05 level (t = -0.41, d = 0.16, p = .683)
(Appendix D). The length of supportive oxygen therapy, length of HFO therapy, PICU
LOS, and hospitalized LOS were independent of each other.
Discussion
The results of general unit-based HFO therapy for bronchiolitis care demonstrated
no significant differences in length of supportive oxygen therapy, length of HFO therapy,
or PICU LOS when compared to the former PICU focused HFO therapy based care.
Although a significant difference among rate of PICU transfers, rate of initial PICU
admits, and total hospital LOS was not established between groups, the frequency of
initial PICU transfers decreased by 54.5%, the frequency of initial PICU admissions
decreased by 27%, and the total hospital LOS decreased by 15 hours, which is clinically
significant.
A strength of this study was the homogeneity of sample sizes between the two
cohorts for comparison. There were several limitations to this project, including the
utilization of a non-randomized design at a single site of study which restricted the ability
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to control for confounding variables (e.g., seasonability, viral trends, overlapping
diagnoses, or unknown patient factors). Likewise, the homogeneity of the sample
patients’ characteristics limited the generalizability of the results. A decrease in the
number of potential subjects in the 2020 cohort could be attributed to the COVID-19
pandemic which began in March 2020. This study’s clinical site experienced a record low
number of pediatric admissions in early 2020 because daycares were closed, and people
practiced social distancing, effectively eliminating the transmission of many respiratory
viruses. In addition, patients in the 2020 cohort did not receive HFO therapy via the same
delivery system as patients in the 2019 cohort. Due to equipment constraints, the 2020
cohort received HFO therapy via a standard NC and oxygen bubbler bottle, rather than
the 2019 cohort, who received HFO therapy via heaters and a larger bore Optiflow circuit
(increased flow rates, higher levels of humidity, and heat). This change in delivery
system could account for the results not demonstrating a difference in length of
supportive oxygen therapy. Further research is recommended with utilization of a more
diverse sample. Larger sample sizes and studies that encompass the entire bronchiolitis
season are also recommended to further strengthen results. Investigations on the effects
of HFO use on physiologic factors (HR, RR, SpO2) might be helpful for their safe use
outside of a PICU setting. An implication for practice from this study was the use of HFO
therapy on the general unit being associated with a decrease in frequency of PICU
transfers, initial PICU admissions, and a decrease in total hospital LOS, yet no changes
occurred in length of supportive oxygen therapy, length of HFO therapy, or PICU LOS.
Conclusion
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The introduction of a process change for the use of HFO therapy on the general
pediatric unit in a large, suburban, Midwestern hospital was associated with a 54.5%
decrease in PICU transfers, a 27% decrease in the frequency of initial PICU admissions,
and a decrease in total hospital LOS by 15 hours. However, there were no changes in
length of supportive oxygen therapy, length of HFO therapy, or PICU LOS. Based upon
this study, the application of HFO therapy for a bronchiolitis illness on a general pediatric
unit did not negatively impact patient care. Considerations for HFO therapy use should be
made as bronchiolitis remains responsible for a considerable amount of pediatric
inpatient hospitalizations, is associated with an increased risk of respiratory distress, and
may require additional hospital resources.
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Appendix A
Table 1. 2019 & 2020 Cohort Demographics

Gender – no (%)
Male
Female
Race – no (%)
Caucasian
African-American
Indian
Age – no (%)
Mean weeks (SD)
2-weeks
3-weeks
4-weeks
5-weeks
6-weeks
7-weeks
8-weeks
12-weeks
16-weeks
20-weeks
28-weeks
32-weeks
40-weeks
44-weeks
48-weeks
Initial Unit Admissions

2019 Cohort

2020 Cohort

10 (77%)
3 (23%)

5 (33.3%)
10 (66.7%)

12 (92.3%)
1 (7.7%)

10 (66.7%)
3 (20%)
2 (13.3%)

9.8 (5.6)
1 (7.7%)

24.9 (18.2)

1 (7.7%)
2 (15.4%)
1 (7.7%)
3 (23%)
1 (7.7%)
3 (23%)
1 (7.5%)

1 (6.6%)
1 (6.6)
1 (6.6%)
1 (6.6%)
1 (6.6%)
1 (6.6%)
1 (6.6%)
1 (6.6%)
1 (6.6%)
1 (6.6%)
4 (26.6%)
1 (6.6%)

6 (46%)

11 (73%)

7 (54%)

4 (27%)

6/6 (100%)

5/11 (45.5%)

Initial PICU Admissions
PICU Transfers
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Appendix B
Figure 1. 2019 Cohort Compared to 2020 Cohort

2019 Cohort Compared to 2020 Cohort
8

Number of Patients

7
6
5
4
3
2
1
0

Initial Unit Admit, no PICU
Transfer

Initial Unit Admit, PICU Tranfer

Initial PICU Admit

Disposition
2019 Cohort

2020 Cohort

Note. A Fischer’s Exact Test was used to examine if general unit admissions and PICU
transfers were independent of each other in the 2020 cohort. The initial general unit
admission rate in the 2020 cohort was 11 but five were transferred to the PICU (p =
.231). Hence, in 2020, a general unit admission was not likely to result in a transfer to
the PICU. A nonparametric test was unable to be performed on the 2019 cohort data due
to the perfect collinearity of the data.
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Figures 2 – 5. Supportive Oxygen Therapy compared with LOS and length of HFO
therapy.
Figure 2. 2019 Cohort – LOS compared to Length of Oxygen Therapy

Note. rp = 0.95, p < .001
Figure 3. 2020 Cohort – LOS compared to Length of Oxygen Therapy

Note. rp = 1.00, p < .001
Figure 4. 2020 Cohort – Length of Supportive Oxygen Therapy compared to Length of
HFO Therapy

Note. rp = 0.77, p = 0.15
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Figure 5. 2020 Cohort – LOS compared to Length of HFO Therapy

Note. rp = 0.80, p = 0.10
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Appendix D
Figure 6. Differences in Length of Supportive Oxygen Therapy and LOS

Note: Length of oxygen therapy: p = .933
Length of HFO therapy: p = .448
PICU LOS: p = .154
LOS: p = .683
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